During the last year, we have seen a substantial increase in the number of studies that are being conducted on cannabis. One of the significant areas of focus for the medical cannabis industry is related to how cannabis can replace opioids and we consider this to be an important topic of discussion.
A few weeks ago, Ethos Cannabis announced a major milestone and launched an opiate-use study with Sidney Kimmel Medical College at Thomas Jefferson University. The study will assess the viability of medical cannabis as an opioid replacement therapeutic aid and we are favorable on this. The purpose of this study is to learn if medical cannabis helps people who currently take opioid pain medication to treat chronic pain and Jefferson hopes to learn if medical cannabis could replace opioids for people who are struggling with opioid use disorder or opioid dependency.
According to the United States Department of Health and Human Services, more than 10 million people misused opioids in 2019. Early research that is being conducted on medical cannabis has been positive and shows the potential it has to treat people who are dependent on opioids. Unfortunately, cannabis remains illegal at the federal level and this has limited the amount of research that is available on the topic.
Earlier this year, GW Pharmaceuticals plc was acquired by Jazz Pharmaceuticals plc (Nasdaq: JAZZ) in a transaction that valued GW at more than $7 billion. GW was an early mover on the cannabis biotech vertical and launched the first US Food and Drug Administration (FDA) approved cannabis-based therapy in 2018.
Over the next year, we expect companies and research institutions to publish more research on the medical benefits of the cannabis. We believe the cannabis biotech vertical is in the early innings of a major growth cycle and want to highlight some of the studies that are being conducted on the opioid replacement topic.
Khiron and Project Twenty21 is a Partnership to be Aware of
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) is a vertically integrated medical cannabis company that has operations in Latin America and in the Europe Union (EU). The company is highly focused on the medical cannabis market and we are favorable on how the business has advanced so far this year.
Last month, Khiron reported that a study being conducted by Project Twenty 21 showed that medical cannabis dramatically improves quality of life for people who suffer from conditions like chronic pain, Multiple Sclerosis, Tourette’s Syndrome and post-traumatic-stress disorder (PTSD). The study was published in an accredited scientific journal and we are favorable on the relationship between Khiron and Project Twenty 21.
Project Twenty 21 launched in late 2019 at the Royal College of Psychiatrists in London and is the United Kingdom’s (UK) first and largest national medical cannabis registry. Khiron is a founding member of Project Twenty 21 and was the first supplier of EU-GMP high-THC dried cannabis flower to the study.
Through Project Twenty21, eligible patients can access affordable medical cannabis treatment, (monitored by Drug Science which is the UK’s leading independent scientific body on drugs). The goal of the project is to create the UK’s largest body of evidence for the effectiveness and tolerability of medical cannabis to receive additional funding to further prove that the benefits of medical cannabis outweigh the potential risks.
According to the National Institute for Clinical Excellence (NICE), there is little or no evidence that commonly prescribed drugs, such as benzodiazepines or opioids, make any difference to people’s quality of life, pain or psychological distress. There is evidence that opioids can negatively impact people’s quality of life and can result in addiction.
Project Twenty21’s study showed a 50% increase in patients’ self-reported health and ability to lead a more normal life as well as significant improvements in patients’ ability to manage debilitating secondary conditions such as anxiety, insomnia and depression. We find the data to be compelling and expect the relationship to serve as a potential growth catalyst for Khiron.
Ethos: Conducting an Important Study with a Leading University
Ethos Cannabis is a private company that is focused on the biotech side of the cannabis industry and we are favorable on the study that it is working on with Sidney Kimmel Medical College at Thomas Jefferson University.
Last month, Ethos announced the official launch of an opiate-use study with the university to assess the viability of medical cannabis as an opioid replacement therapeutic aid. The purpose of this study is to learn if medical cannabis can help people who suffer from chronic pain and are taking opioid pain medication.
The university hopes to determine if medical cannabis could replace opioids for those struggling with opioid use disorder or opioid dependency and we are favorable on the impact that positive results could have on the cannabis sector. If the study can prove that medical cannabis can be used as an opioid replacement therapeutic aid, we expect to see a spike in interest in cannabis companies that are focused on this aspect of the industry and would believe that it would serve as a catalyst for the entire sector.
If you are interested in learning more about companies that are working to replace opioids with medical cannabis, please send an email to email@example.com to be added to our distribution list.
For the fastest access to data on this vertical of the cannabis industry, you can sign up for our free newsletter!
Pursuant to an agreement between StoneBridge Partners LLC and Khiron Life Sciences Inc. (KHRN) we have been hired for a period of 90 days beginning May 5, 2021 and ending August 5, 2021 to publicly disseminate information about (KHRN) including on the Website and other media including Facebook and Twitter. We are being paid $6,000 per month (KHRN) for or were paid “0” shares of restricted common shares. We own zero shares of (KHRN), which we purchased in the open market. We plan to sell the “ZERO” shares of (KHRN) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (KHRN) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.